Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has received a consensus rating of “Hold” from the six analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $51.00.

Several research analysts have recently issued reports on AIMT shares. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, July 27th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $45.00 target price (up previously from $36.00) on shares of Aimmune Therapeutics in a research note on Monday. Wedbush reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, July 24th. Finally, BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th.

In other news, CEO Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $25.01, for a total value of $2,501,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Susan E. Barrowcliffe sold 18,390 shares of Aimmune Therapeutics stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $22.00, for a total transaction of $404,580.00. Following the completion of the sale, the insider now owns 3,223 shares in the company, valued at $70,906. The disclosure for this sale can be found here. Insiders sold 325,000 shares of company stock worth $7,922,482 over the last quarter. 24.56% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. raised its holdings in shares of Aimmune Therapeutics by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company’s stock valued at $1,892,000 after purchasing an additional 4,788 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Aimmune Therapeutics in the second quarter valued at approximately $442,000. Bank of New York Mellon Corp raised its holdings in shares of Aimmune Therapeutics by 16.9% in the second quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock valued at $2,700,000 after purchasing an additional 19,016 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Aimmune Therapeutics in the second quarter valued at approximately $360,000. Finally, Credit Suisse AG raised its holdings in shares of Aimmune Therapeutics by 14.1% in the first quarter. Credit Suisse AG now owns 42,445 shares of the biotechnology company’s stock valued at $924,000 after purchasing an additional 5,248 shares during the last quarter. Institutional investors own 72.90% of the company’s stock.

Shares of Aimmune Therapeutics (AIMT) traded up 28.8001% during midday trading on Monday, reaching $33.0501. 3,941,189 shares of the company were exchanged. Aimmune Therapeutics has a 52-week low of $14.87 and a 52-week high of $37.50. The company’s 50-day moving average price is $24.75 and its 200 day moving average price is $24.75. The stock’s market capitalization is $1.67 billion.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01). On average, equities analysts predict that Aimmune Therapeutics will post ($2.71) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/23/aimmune-therapeutics-inc-aimt-given-consensus-recommendation-of-hold-by-brokerages-2.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.